肝细胞癌（ HCC ）是全球最常见的癌症之一，在癌症相关死亡发生率方面排名第三。全球每年诊断出超过500000例新病例。HCC的发病率和患病率呈上升趋势，大多数疾病负担在病毒性乙型肝炎流行的亚洲。
适应症：HCC - Hepatocellular Carcinoma、Unresectable Hepatocellular Carcinoma
入组条件
纳入标准
- Diagnosis of HCC is made according to American Association for the Study of Liver Diseases (AASLD) practice guideline 2010: patients with cirrhosis of any etiology and patients with chronic hepatitis B (HBV) who may not have fully developed cirrhosis, the presence of liver nodule \>1cm and demonstrated in a single contrast enhanced dynamic imaging \[either computed tomography (CT) or magnetic resonance imaging (MRI)\] of intense arterial uptake and "washout" in portal venous and delayed phases.
- Tumor size 5-25 cm or number of lesions ≤3 or segmental portal vein involvement
- Age: 18-80 years old
- Child Pugh liver function class A-B7
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
排除标准
- Prior invasive malignancy
- Prior radiotherapy to the region of liver or selective internal radiotherapy
- Severe, active co-morbidity
- Presence of extra-hepatic metastases (M1)
- Main portal vein or inferior vena cava (IVC) thrombosis or involvement
- Presence of ascites or encephalopathy
- Contraindicated of SBRT:
- Any one hepatocellular carcinoma \> 15 cm
- Total maximal sum of hepatocellular carcinoma \> 25 cm
- More than 3 discrete hepatic nodule
- Direct tumor extension into the stomach, duodenum, small bowel, large bowel, common or main branch of biliary tree
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。